310 related articles for article (PubMed ID: 16244105)
1. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators.
Cassatella MA; Huber V; Calzetti F; Margotto D; Tamassia N; Peri G; Mantovani A; Rivoltini L; Tecchio C
J Leukoc Biol; 2006 Jan; 79(1):123-32. PubMed ID: 16244105
[TBL] [Abstract][Full Text] [Related]
2. On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils.
Cassatella MA
J Leukoc Biol; 2006 Jun; 79(6):1140-9. PubMed ID: 16574768
[TBL] [Abstract][Full Text] [Related]
3. Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells.
Oshima K; Yanase N; Ibukiyama C; Yamashina A; Kayagaki N; Yagita H; Mizuguchi J
Cytokine; 2001 May; 14(4):193-201. PubMed ID: 11448118
[TBL] [Abstract][Full Text] [Related]
4. Interferon (IFN)-gamma is a main mediator of keratinocyte (HaCaT) apoptosis and contributes to autocrine IFN-gamma and tumour necrosis factor-alpha production.
Konur A; Schulz U; Eissner G; Andreesen R; Holler E
Br J Dermatol; 2005 Jun; 152(6):1134-42. PubMed ID: 15948973
[TBL] [Abstract][Full Text] [Related]
5. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets.
Crist SA; Elzey BD; Ludwig AT; Griffith TS; Staack JB; Lentz SR; Ratliff TL
Exp Hematol; 2004 Nov; 32(11):1073-81. PubMed ID: 15539085
[TBL] [Abstract][Full Text] [Related]
6. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
Ishikawa E; Nakazawa M; Yoshinari M; Minami M
J Virol; 2005 Jun; 79(12):7658-63. PubMed ID: 15919918
[TBL] [Abstract][Full Text] [Related]
7. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
8. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K
Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharides-activated human astroglioma cells induce apoptotic death of T-lymphocytes via c-Jun N-terminal kinases-dependent up-regulation of TRAIL.
Kwon D; Cheong JH; Lee JC; Kwon JH; Kim WK
Neurosci Res; 2006 Apr; 54(4):338-43. PubMed ID: 16442178
[TBL] [Abstract][Full Text] [Related]
10. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
[TBL] [Abstract][Full Text] [Related]
11. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions.
Begue B; Wajant H; Bambou JC; Dubuquoy L; Siegmund D; Beaulieu JF; Canioni D; Berrebi D; Brousse N; Desreumaux P; Schmitz J; Lentze MJ; Goulet O; Cerf-Bensussan N; Ruemmele FM
Gastroenterology; 2006 Jun; 130(7):1962-74. PubMed ID: 16762619
[TBL] [Abstract][Full Text] [Related]
12. Knock down of p53 levels in human keratinocytes increases susceptibility to type I and type II interferon-induced apoptosis mediated by a TRAIL dependent pathway.
Chaturvedi V; Bodner B; Qin JZ; Nickoloff BJ
J Dermatol Sci; 2006 Jan; 41(1):31-41. PubMed ID: 16289694
[TBL] [Abstract][Full Text] [Related]
13. Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells.
Yanase N; Hata K; Shimo K; Hayashida M; Evers BM; Mizuguchi J
Exp Cell Res; 2005 Oct; 310(1):10-21. PubMed ID: 16099454
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of adenosine receptors in human neutrophils: up-regulation by specific Th1 cytokines and lipopolysaccharide.
Fortin A; Harbour D; Fernandes M; Borgeat P; Bourgoin S
J Leukoc Biol; 2006 Mar; 79(3):574-85. PubMed ID: 16387843
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
16. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
17. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation.
Jung EM; Park JW; Choi KS; Park JW; Lee HI; Lee KS; Kwon TK
Carcinogenesis; 2006 Oct; 27(10):2008-17. PubMed ID: 16613838
[TBL] [Abstract][Full Text] [Related]
18. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.
Kamohara H; Matsuyama W; Shimozato O; Abe K; Galligan C; Hashimoto S; Matsushima K; Yoshimura T
Immunology; 2004 Feb; 111(2):186-94. PubMed ID: 15027904
[TBL] [Abstract][Full Text] [Related]
19. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack.
Martínez-Lorenzo MJ; Anel A; Alava MA; Piñeiro A; Naval J; Lasierra P; Larrad L
Exp Cell Res; 2004 May; 295(2):315-29. PubMed ID: 15093732
[TBL] [Abstract][Full Text] [Related]
20. Type I interferon and TNFalpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells.
Abadie A; Besançon F; Wietzerbin J
Oncogene; 2004 Jun; 23(28):4911-20. PubMed ID: 15077162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
